|
India Intensifies Site Inspections in Response to Infant Deaths
The Drugs Controller General of India (DCGI) is increasing inspections of clinical trial sites rather than imposing new regulations in the wake of two recent incidents in which infants died in studies sponsored by multinational drug companies, an industry expert says.
This article is viewable by subscribers only. To view this article, please select an option below.
|
Subscribe
Archives